DOSAGE INDEX / BLEND
AOD-9604 + CJC-1295 + Ipamorelin
Research, reported schedules and supply planning.
Review the triple blend through AOD-9604 animal and human evidence, CJC identity questions and the direct comparisons needed for metabolic claims.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- AOD: 200–400 micrograms; CJC and ipamorelin: 100–200 micrograms each, per day
- Frequency
- Once daily
- Cycle / observation period
- 8–12 weeks; source also mentions 16 weeks
- Route / research model
- Subcutaneous
The source assumes a 6:3:3 mg blend. Component research does not establish the safety or efficacy of this fixed combination.
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Acidic diluent / GA water: under formulation review. Acetic-acid concentration, glycerin content, peptide salt form and intended laboratory use must be specified before compatibility can be assessed. No acidic diluent has been assigned to this product or blend.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 12 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
Studies of individual ingredients do not establish the effects of this finished combination. Combination studies are identified explicitly below.
- AOD-9604 has animal metabolic research, while FDA's 2024 scientific review describes a larger oral obesity trial that did not show a significant primary weight-loss advantage over placebo. Neither record tests this blend. [1] [2]
- A 2001 study reported reduced body weight and fat after repeated AOD-9604 treatment in obese mice and investigated beta-adrenergic pathway relationships. Those findings were preclinical and did not involve CJC-1295 or ipamorelin. [1]
- FDA's 2024 review describes the OPTIONS oral trial, with 536 enrolled and 502 randomized participants. It reports no significant primary weight-loss difference from placebo and describes the sponsor's termination of obesity development. The review also notes limitations in the available clinical reporting. [2]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 15 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.
- Original animal study
- FDA evidence assessment
- Bachem: peptide solubility and handling guidance (laboratory methods)
- Journal of Endocrinology & Metabolism (2014)Further reading · Listed in reference bibliography.
- Journal of Clinical Endocrinology & Metabolism (PubMed)Further reading · Listed in reference bibliography.
- European Journal of Endocrinology (PubMed)Further reading · Listed in reference bibliography.
- Translational Andrology and Urology (PMC)Further reading · Listed in reference bibliography.
- Endocrinology (OUP)Further reading · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
- Journal of Endocrinology & Metabolism (2013)Further reading · Listed in reference bibliography.
- Obesity Pharmacotherapy Review (PMC)Further reading · Listed in reference bibliography.
- Subcutaneous Drug Injection Review (PMC)Further reading · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
- MedlinePlusGeneral guidance · Listed in reference bibliography.
- NCBI BookshelfFurther reading · Listed in reference bibliography.
- Central & Peripheral Anti-Obesity Targets (PMC)Further reading · Listed in reference bibliography.
- PubMedFurther reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.